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1. Introduction  
Cade described the effects of lithium on manic episodes in 1949.  Schou confirmed these 
initial observations in 1954. From 1949 until today we can speak of the history of 
psychopharmacology, in fact it is the oldest drug in mental disorders that is still in full use 
(Johson, 2006).  
The Food and Drug Administration (FDA) approved it in 1970 for the treatment of acute 
mania and in 1974 for the prophylaxis of bipolar disorder.  
Today lithium valid indications remain in force: acute mania, bipolar depression, prophylaxis 
and maintenance of bipolar disorder and unipolar depression. Moreover, its use has also been 
extended to many diseases: personality disorders, aggression, anxiety, etc. (Freeman, 2006). 
However, it is a drug whose management requires detailed knowledge of their numerous 
side effects (Table 1), as well as drug interactions (Table 2), contraindications and special 
situations (Álvarez, 2000). The fact that it is a drug with a very narrow therapeutic window, 
requires frequent monitoring plasma determinations. 
We report a case that has, in principle, one of the most common side effects of using this 
drug, 25 to 35 percent of patients have polyuria and polydipsia (Sadock, 2004), a person who 
concurrently also presents serious illnesses which require special surveillance. But a close 
examination proved to be another slightly different pathology documented. 
Central diabetes insipidus (CDI) is a condition characterized by polyuria, polydipsia, and 
nocturia and is due to deficiency of arginine vasopressin (AVP). 
The case has already been published four years ago in a Spanish journal (Gil-Díez, 2007), but 
we consider it of interest in order to report on the progress of the disease and a bibliographic 
update.  
2. Case report 
A 61 year old woman diagnosed with bipolar disorder since the age of 18. She was 
frequently hospitalized due to depressive episodes and treated with lithium for about 19 
years with excellent results.        
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Cardiovascular system Sinus Node dysfunction 
ECG changes 
Myocardial disorders (myocarditis) 
Kidney On Glomerular Filtration Rate (GFR) 
On Serum Creatinine 
On Distal Tubular function 
Renal Tubular acidosis 
Proteinuria 
Morphologic changes 
Body weight Increase 
Nervous System Acute toxicity 
Permanent cognitive impairment 
Cognitive functions altered 
Haematology Leukocytosis 
Skin & Skin appendages Skin Rash 
Psoriasis 
Acne 
Alopecia  
Endocrinous System Hypothyroidism 
Increased Calcium plasma levels 
Glycemic disorders 
Gastrointestinal System Diarrhea 
Vomiting 
Constipation 
Metalic taste 
Sexual function Sexual dysfunction  
Table 1. Main Lithium side effects. 
Family history: A mother and a brother diagnosed with affective disorder who died by 
suicide. 
Significant medical history and treatment with various specialists: Primary autoimmune 
hypothyroidism with an adequate replacement therapy treatment, Diabetes mellitus type 2 
with current good metabolic control, hypercholesterolemia and obesity. 
She was continuously treated with lithium 600 mg three times a day, with appropriate 
lithemia plasma levels. 
Concomitant treatment: Risperidone 3 (0 – 0 - 1/2), Quetiapine 200 (0 - 0 - 1), Levothyroxine 
100 (1 before breakfast), Glycazide 30 (1/2 – 1/2 – 0) and Symvastatine 40 (1 at bedtime). 
In July 2006, she was admitted for severe depressive episode with suicidal ideation and 
Paroxetine was added to her treatment. A few days later she suffered from fever, stupor, 
and myoclonus. Among the studies carried out a plasma lithemia of 1.03 mEq/l was 
highlighted. Psychotropic treatment was discontinued and she was referred to the Internal 
Medicine Department. Facing the possibility of a meningo-encephalitis, laboratory tests and 
CT scan were performed. She was treated empirically with acyclovir, ceftriaxone, and 
ampicillin, which lead to the disappearance of the fever and other satisfactory outcomes. 
Micrococcus sp was isolated from blood cultures. 
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Drug Effect Risk* 
Ansiolitic 
- alprazolam, clonazepam 
 
> lithemia due to > oral lithium absortion 
 
3 
Anticonvulsivants 
- carbamazepine/valproate 
- lamotrigine/gabapentin 
 
> lithemia, neurotoxicity risk 
¿? 
 
2 
3 
Antidepressants 
- SSRI 
- Tricyclic 
- MAOIs 
 
> lithemia, serotonin sd. Risk 
¿? lithemia, > tremor 
¿? lithemia, serotonin sd. Risk 
 
2 
2 
2 
Antipsychotics 
- Atypical 
- Classical 
 
> lithemia 
¿? 
 
2 
2 
Calcium Channel Blockers 
- verapamil, diltiazem 
 
possible synergism 
 
1 
Risk: (1) Interaction risk, use only if necessary, surveillance; (2) potentially hazard, 
surveillance; (3) safe, mild discomfort 
Table 2. Lithium interactions with other psychotropic drugs 
In this context, high blood sodium levels (164 mEq/l), polyuria and polydipsia were 
presented. The urine had an osmolarity of 369, lower than would correspond to blood 
osmolarity of 353 mOsm/kg. The values of 24-hour urine cortisol were increased but with 
normal baseline figures for plasma cortisol. Also presenting: ADH: 2.8 pg/ml, aldosterone: 
273 pg/ml, renin: 0.7 ng/ml/h. Abdominal CT is performed to assess adrenal glands and 
new determinations of urinary cortisol, ACTH and DHEA plasma levels, all within the 
normal range. It was thought in diabetes insipidus and detailed assessment was made of 
Nephrology and Endocrinology Services, to confirm whether it was central or nephrogenic 
diabetes.  
The results of analytical determinations carried out are detailed as follows: 
Serum chemistries:  
- Blood glucose (82 mg/dl.), Urea (38 mg/dl.), Creatinine (0.66 mg/dl.), Uric acid (5.9 
mg/dl.), Triglycerides (151 mg/dl.), Cholesterol (265 mg/dl.), HDL-cholesterol (53 
mg/dl.), LDL-cholesterol (182 mg/dl.), Electrolytes (BUN, creatinine, Na, K, Cl all 
within normal range), Calcium (9.2 mg/dl.), Phosphorus (3.6 mg/dl.), transaminases 
(normal), blood osmolarity (296 mOsm/Kg.), urine osmolarity in 24 hours (197 
mOsm/Kg.), diuresis (4500ml.),  
- Nugent test: after administration of 1 mg of Dexamethasone, Cortisol levels post-
dexametasone 0.63 mcg/dl. 
- Thyroid function: thyroxine free (0.75 ng/dl.), TSH (3.75 mIU/l), FSH (14.1 IU/l), LH 
(3.72 IU/l.) 
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- Cortisol in urine 24 hours (65 mcg.),  
- Estradiol (29 pg/ml.), 
- Growth Hormone (baseline: 0.4 ng/ml. – After 15’ lower than 0.3 ng/ml.), 
- Prolactin (previous baseline values: 9.1 and 5.8 ng/ml.) 
The water deprivation test (WDT) is performed followed by desmopressin injection 
(DDAVP test). Both test results (table 3) were compatible with partial central diabetes 
insipidus, due to the appearance of urine concentration after a desmopressin injection as 
shown in the following results: 
- Blood osmolarity at 08:30 h: 297 mOsm/kg.; at 11:30 h: 304 mOsm/kg.; at 14:00 h: 300 
mosm/kg. 
- In urine from 07:30 to 08:30 h: 138 mOsm/Kg.; from 10:30 h to 11:30 h: 197 mOsm/kg.; 
from 13:30 h to 14:30 h: 154 mOsm/kg. 
- At 14:30 h (with an increased urine osmolality less than 30 mOsm/kg, blood 
osmolarity> 290 and urine> 300), 2 mcg desmopressin was injected subcutaneously. 
- Urine osmolality from 14:30 to 15:30 h: 300 mOsm/kg; from 15:30 to 16:30 h: 402 
mOsm/kg.; from 16:30 to 17:30: 351; from 17:30 to 18:30: 269 mOsm/kg.  
- Osmolality (4 h after desmopressin injecticon): 295 mOsm/kg; ADH: 1.6 pg/ml. Study 
being compatible with partial central diabetes insipidus presenting partial 
concentration of the urine after injection of DDAVP. 
In addition, there were no changes in kidney function.  
 
 Blood Urine 
Osmolality 296 mOsm/Kg 197 mOsm/Kg 
   
Water Deprivation Test   
Osmolarity (mOsm/Kg)at 08:30 h. 297 138 
 11:30 h. 304 197 
 14:00 h. 300 154 
    
DDVP test    
(2 mcgr. Dessmopresin injec.)    
Osmolarity (mOsm/Kg) at 15:30 h.  300 
 16:30 h.  402 
 17:30 h.  351 
 18:30 h. 295 269 
Table 3. Water Deprivation and Vassopresin tests results 
In the WDT (Muller test), urine osmolality is not modified neither in Central Diabetes  
Insipidus nor in Nephrogenic Diabetes Insipidus. 
In DDVP test, urine osmolality is increased > 9% in Central Diabetes Insipidus. 
MRI of the brain and pituitary findings: Partially empty sella, small laminar pituitary gland 
covering the sella’s floor, centred pituitary stalk, no abnormalities suggesting a pathology 
were showed after contrast administration. 
The patient medical history was completed with the following diagnosis: Diabetes insipidus. 
Partially empty sella. Normal pituitary function. 
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Desmopressin therapy was prescribed 0.1 mg every 8 hours. A few days later, the volume of 
urine collected in 24 hours was within acceptable range. 
Since our first study, four years ago, the patient has continued to balance 
psychopathologically and no episodes of mental illness were presented. During this time the 
patient has been treated with lithium and it’s lithemia plasma levels have always been 
within therapeutic range. 
Current treatment: 
Lithium 400 mg (1-1-1),  Clonazepan 2 mg ( ½ - ½ -1),  Escitalopram 15 (1-0 -0), Quetiapine 
100 (0-0-1), Desmopressin 0.1 mg (1-1-1), Levothyroxine 100 (1-0-0), Simvastatin 40 mg (0-0-
1), Gliclazide 30 mg (½ tablet od -breakfast-). 
During this period the patient attended frequent medical controls with analytical testing. In 
all cases the patient has remained stable. Related to central diabetes insipidus has remained 
asymptomatic, with mild polyuria and polydipsia and analytical testing within normal 
range limits. She continued with desmopressin. 
However, the patient was admitted twice for a few days because of respiratory failure and 
moderate pulmonary hypertension. Treatment includes oxygen therapy, tiotropium 18 mcgr 
(one puff od), budesonide and formoterol fumarate 160/4.5 mcgr (one puff bd) and 
torasemide 10 mg (od at breakfast). 
3. Discussion 
Central diabetes insipidus (CDI) is a condition characterized by polyuria and polydipsia due 
to the presence of inadequate secretion of antidiuretic hormone (ADH) or vasopressin by the 
neurohypophysis or posterior pituitary; in the absence of ADH polyuria, itoccurs because 
the patient is unable to concentrate urine.  
Any cause damaging or altering the neurohypophyseal system can lead to CDI (Casanueva, 
1998). Traumatic brain injury or neurosurgery are the most frequent causes, there are also 
primary and inherited forms (Table 4). However, it should be noted that in 25% of cases in 
adults the etiology remains unknown (Catalá, 2007).  
In nephrogenic diabetes insipidus (NDI) lithium interferes with the action of ADH at distal 
tubule and collector level by reducing the sensitivity of adenylate cyclase to vasopressin and 
consequently interfering with the formation of intracellular cAMP.  As some authors 
describe, 10% of patients with the chronic treatment of lithium may develop NDI (Pérez-
Blanco, 2000). 
Differential diagnosis of diabetes insipidus is complex and involves analytical testing (Table 
5) and hypothalamic-pituitary magnetic resonance imaging (MRI), together with the 
consideration of history and the exclusion of other causes (hyperglycemia, hypercalcemia, 
etc.). 
Whilst nephrogenic diabetes insipidus is considered as a possible and relatively common 
effect of lithium, this drug in central diabetes insipidus is rarely involved in its origin. 
According to other authors, the lithium can induce a partial CDI (Pérez-Blanco, 2000). We 
have found few cases documented and the mechanism of action is not known. In all 
references found the population studies are people with lithium treatment who develop 
symptoms of diabetes insipidus by the simultaneous presence of other pathologies: trauma 
(Olson, 2004), aortic stenosis (Hensen, 1997), cavernous sinus thrombosis (Kamijo, 2003). The 
role of lithium in the regulation of ADH release is discussed due to its participation in 
osmolarity and its action on osmoreceptors as controllers of ADH release (Gold, 1983). 
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Genetic or familial: autosomal 
Dominant (mutations of the gene encoding the AVP-neurophysin II) 
Recessive 
Gene mutations inactivating AVP 
X Q28 linked (gene not identified) 
Deletion of chromosome 7q 
Wolfram syndrome (WFS gene mutation, region chromosome 4p16) 
Congenital 
Septo-optical dysplasia 
hypogenesis pituitary 
Cranial midline defects  
Holoprosencephaly 
Acquired 
Head injury 
Neurosurgery 
Neoplasms 
- craniopharyngioma, pituitary adenoma, pinealoma, dysgerminoma, meningioma, 
- metastasis (carcinoma of the lung in male and female breast) 
- hematologic: lymphoma, leukemia 
- granulomas, histiocytosis, Wegener granulomatosis, sarcoidosis 
- infections: chronic meningitis, tuberculosis, syphilis, viral encephalitis, 
toxoplasmosis 
- vascular diseases: Sheehan syndrome, internal carotid aneurysm, bypass surgery, 
hypoxic encephalopathy 
- autoimmune: lymphocytic infundibulohipofisitis  
- inflammatory: lupus erythematosus, scleroderma 
- toxins: Tetrodotoxin, snake venom 
- drugs: ethanol, phenytoin, corticosteroids, alpha agonists 
- idiopathic 
Modified from: Catalá Bouset et al. Guía clínica del diagnóstico y tratamiento de los trastornos de la 
neurohipófisis. Endocrinol Nutr. 2007;54(1):23-33 
Table 4. Etiology of central diabetes insipidus. Modified from Bauset M. (2007) 
 
 
Normal 
Central Diabetes 
Insipidus 
Nephrogenic 
Diabetes Insipidus 
Plasma Osmolality (mOsm/Kg) Normal Increased Increased 
Urine Osmolality (mOsm/Kg) Normal Decreased Decreased 
Urine Osmolality (mOsm/Kg) after water 
deprivation 
> 750 < 300 < 300 
Urine Osmolality (mOsm/Kg) after AVP > 750 > 750 < 300 
Plasma AVP (pmol/l) Normal 
Decreased or 
Normal 
Normal or 
Increased 
AVP: Vasopressin 
Table 5. Diabetes Insipidus differential diagnoses 
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In our case it is appropriate to note the existence of viral encephalitis in the appearance of 
the picture, so it is worth recalling the pathological images of sella and pituitary findings. 
Anyway, the case illustrates the difficulties of management of some patients with lithium, 
and the need for a differential diagnosis in the presence of diabetes insipidus (Posner, 1996) 
The treatment is also completely different. In central diabetes insipidus desmopressin is the 
drug of choice for treatment. It is a synthetic analogue of vasopressin, which has a potent 
antidiuretic effect. In our case, over 4 years has been effective, and did not change the serum 
sodium levels (one of the risks of use) (Catalá, 2007). 
4. References  
Álvarez, E., Pérez, V., & Pérez, J. (2000). Clínica de litio: Teoría y práctica. ISBN 8495035146, 
Barcelona: Permanyer. 
Casanueva Freijo, F. (1995). Enfermedades del sistema hipotálamo-hipofisario. In A. 
Domarus, P. Farreras Valenti, & C. Rozman (Eds.), Medicina interna (13ª ed.). ISBN 
848174106X, Madrid: Mosby/Doyma Libros. 
Català Bauset, M., Gilsanz Peral, A., Tortosa Henzi, F., Zugasti Murillo, A., Moreno Esteban, 
B. & et al. (2007). Guía clínica del diagnóstico y tratamiento de los trastornos de la 
neurohipófisis. Endocrinología Y Nutrición, 54(1), 23-33. ISSN 1575-0922 
Freeman, M. P., Wiegand, C., & Gelemberg, A. J. (2006). Litio. In A. F. Schatzberg & C. B. 
Nemeroff (Eds.), Tratado de psicofarmacología. (pp. 597-617). ISBN 9788445814260, 
Barcelona: Masson. 
Gil-Díez Usandigaza, C., Cañas Cañas, M., Sanguino Andrés, R. M. & González Pablos, E. 
(2007). Un caso de diabetes insípida central en una paciente con trastorno bipolar 
consumidora de litio desde hace años. Anales de psiquiatría,Vol. 23, No. 5, pp. (253-
255), ISSN 0213-0599 
Gold, P. W., Robertson, G. L., Post, R. M., Kaye, W., Ballenger, J., Rubinow, D., & Goodwin, 
F. K. (1983). The effect of lithium on the osmoregulation of arginine vasopressin 
secretion. The Journal of Clinical Endocrinology and Metabolism, 56(2), 295-9. ISSN 
0021-972X 
Hensen, J., Seufferlein, T., & Oelkers, W. (1997). Atherosclerosis, aortic stenosis and sudden 
onset central diabetes insipidus. Experimental and Clinical Endocrinology & Diabetes : 
Official Journal, German Society of Endocrinology [And] German Diabetes Association, 
105(4), 227-33. ISSN 0947-7349 
Johson, G. (2006). Eutimizantes (I). El descubrimiento de las propiedades antimaníacas de 
las sales de litio. . In F. López-Muñoz & C. Álamo (Eds.), Historia de la 
psicofarmacología (2006 ed.). (pp. 761-9). ISBN 9788479034580, Madrid: Médica 
Panamericana. 
Kamijo, Y., Soma, K., Hamanaka, S., Nagai, T., & Kurihara, K. (2003). Dural sinus 
thrombosis with severe hypernatremia developing in a patient on long-term 
lithium therapy. Journal of Toxicology. Clinical Toxicology, 41(4), 359-62. ISSN 0731-
3810 
Olson, D. M., Meek, L. G., & Lynch, J. R. (2004). Accurate patient history contributes to 
differentiating diabetes insipidus: A case study. The Journal of Neuroscience Nursing : 
Journal of the American Association of Neuroscience Nurses, 36(4), 228-30. ISSN 0888-
0395 
www.intechopen.com
 
Diabetes Insipidus 
 
108 
Pérez-Blanco, J. (2000). Efectos secundarios I: Sistema cardiovascular, riñón, peso. In A. 
Álvarez, V. Pérez, & J. Pérez (Eds.), Clínica de litio: Teoría y práctica. (pp. 121-36). 
ISBN 8495035146, Barcelona: Permanyer. 
Posner, L., & Mokrzycki, M. H. (1996). Transient central diabetes insipidus in the setting of 
underlying chronic nephrogenic diabetes insipidus associated with lithium use. 
American Journal of Nephrology, 16(4), 339-43. ISSN 0250-8095 
Sadock, B. J., Kaplan, H. I., & Sadock, V. A. (2007). Kaplan & sadock's synopsis of psychiatry: 
Behavioral sciences/clinical psychiatry. ISBN 9780781773270, Philadelphia: Lippincott 
Williams & Wilkins.  
www.intechopen.com
Diabetes Insipidus
Edited by Prof. Kyuzi Kamoi
ISBN 978-953-307-367-5
Hard cover, 140 pages
Publisher InTech
Published online 14, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The first chapter of the book reports on the management of Langerhans cell histiocytosis (LCH)-induced
central diabetes insipidus and its associated endocrinological/neurological sequelae in the national survey. The
next chapter addresses DI and head injuries. Next, the management of neuroendocrine instability during
maintenance of potential organ donors is described. Organ transplants have gradually increased worldwide.
To have maintenance of appropriate potential organs, AVP is needed. Furthermore, nephrogenic DI-the
potential therapeutic drugs and analysis of membrane protein stability is the topic of the next two chapters,
followed by new insights into the diagnosis and management of pregnancy-related DI. The seventh chapter
reports on the problems with differential diagnosis in a case of central DI in a female patient with bipolar
disorder. The lithium treatment usually resulted in nephrogenic DI. Finally, over the last years, the
development of MRI imaging on the pituitary gland with the stalk and hypothalamus has advanced. The final
chapter interprets imaging techniques in DI in detail.
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